Beacon Therapeutics Reported Positive Gene Therapy Results
The company revealed Phase 2 VISTA trial data showing visual improvement in patients with X-linked retinitis pigmentosa.
Updated on Oct. 12, 2026 in Biotech
Live Poll
Should the government prioritize fast-track approval for new gene therapies targeting rare, incurable diseases?
Beacon Therapeutics presented findings from its VISTA trial, showing that laru-zova gene therapy improved visual acuity in patients with X-linked retinitis pigmentosa. The results were shared at the American Academy of Ophthalmology annual meeting.
Why it matters
The trial data offers a potential advancement for treating X-linked retinitis pigmentosa, a condition that currently has few therapeutic options. Positive outcomes at the 12-month mark provide evidence for the efficacy of subretinal gene therapy.
The VISTA trial enrolled 85 male participants aged 12 to 48 and tested dosages of 6.8 E+11 vg/eye and 3.7 E+11 vg/eye. No patients in the untreated control group achieved the measured 15-letter improvement in low luminance visual acuity at 12 months.
The players
Beacon Therapeutics
This biotechnology company focuses on the development of gene therapies to treat various ocular diseases.
American Academy of Ophthalmology
This professional organization represents ophthalmologists and provides ongoing education and research forums for the eye care community.
The details
Researchers utilized subretinal injections of laru-zova and tracked outcomes using microperimetry and low luminance visual acuity tests. While the treatment showed efficacy, adverse events related to the therapy occurred in 25% of high dose and 38% of low dose participants.
Timeline
The American Academy of Ophthalmology annual meeting took place October 9-12, 2026.
Results from the VISTA trial were presented on October 10, 2026.
A summary of the data was published on October 12, 2026.
The Big Picture
This study follows a pattern of clinical investigations aimed at validating gene therapy for inherited retinal degenerations under the VISTA trial. The findings mark a shift in how researchers approach treating X-linked retinitis pigmentosa through targeted genetic intervention.
The trial indicates that gene therapy may eventually provide a viable treatment option for patients currently facing vision loss from X-linked retinitis pigmentosa. Future regulatory approval will determine when and how patients can access this therapy through specialized medical providers.
The takeaway
The successful meeting of the primary endpoint suggests that targeted gene therapy is becoming an increasingly effective tool for treating rare inherited eye conditions. Patients and families should monitor future regulatory updates to track the development of this treatment toward potential commercial availability.
What happens next
Beacon Therapeutics intends to begin a rolling Biologics License Application submission to regulators in 2026.
Further reading
For more information on the evolving landscape of genetic medicine, visit our Biotech section.
Live Poll
Should the government prioritize fast-track approval for new gene therapies targeting rare, incurable diseases?
